Zoetis (NYSE:ZTS) Given New $200.00 Price Target at Piper Sandler

Zoetis (NYSE:ZTS) had its price objective trimmed by Piper Sandler from $210.00 to $200.00 in a research report report published on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities analysts also recently issued research reports about the company. Morgan Stanley decreased their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $214.00.

Zoetis Stock Up 0.2 %

Shares of NYSE ZTS opened at $171.71 on Monday. The stock has a market capitalization of $77.47 billion, a P/E ratio of 32.28, a PEG ratio of 2.77 and a beta of 0.90. The firm’s 50 day simple moving average is $169.26 and its two-hundred day simple moving average is $179.21. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a one year low of $144.80 and a one year high of $200.53.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.16%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 37.59%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mizuho Securities USA LLC grew its position in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Zoetis in the fourth quarter valued at approximately $196,651,000. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. International Assets Investment Management LLC raised its holdings in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares in the last quarter. Finally, Amundi lifted its position in Zoetis by 46.2% in the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock worth $453,355,000 after purchasing an additional 867,993 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.